Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658124 | 0.93 | NR4A2 (0.54) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL14188728 | 0.90 | NR4A2 (0.51) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL14215657 | 0.85 | KDM4E (0.46) | NR4A2MEN1ALDH1A1KMT2AMTNR1A | |
| Lynamicin A SCHEMBL12658027 | 0.85 | NR4A2 (0.61) | NR4A2MEN1NPC1ALDH1A1GAA | |
| SCHEMBL12658270 | 0.82 | NR4A2 (0.45) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL12658127 | 0.81 | NR4A2 (0.57) | NR4A2MEN1ALDH1A1CYP1A2GAA | |
| Lynamicin B SCHEMBL12658014 | 0.80 | NR4A2 (0.55) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL12658205 | 0.79 | NR4A2 (0.44) | NR4A2MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14188735 | 0.79 | NR4A2 (0.52) | NR4A2MEN1ALDH1A1GAAMAPT | |
| SCHEMBL14188730 | 0.79 | NR4A2 (0.54) | NR4A2MEN1NPC1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711486-B1 | BIS-INDOLE PYRROLES USEFUL AS ANTIMICROBIAL AGENTS | NEREUS PHARMACEUTICALS INC (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7375129-B2 | Bis-indole pyrroles useful as antimicrobials agents | NEREUS PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-20070149601-A1 | Bis-indole pyrroles useful as antimicrobials agents | PRIVATE LIFE BIOMED AG (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149601-A1 | Bis-indole pyrroles useful as antimicrobials agents | PRIVATE LIFE BIOMED AG (DE) | 2007-06-28 | — | — | US | disclosed |
| US-7166634-B2 | Bis-indole pyrroles useful as antimicrobials agents | NEREUS PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166634-B2 | Bis-indole pyrroles useful as antimicrobials agents | NEREUS PHARMACEUTICALS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149601-A1 | Bis-indole pyrroles useful as antimicrobials agents | IDO1, IDO2, TPH1 | NR4A2 4802/4885GABRA1 1816/4885GABRB1 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.